REGENCY Studie
Laufzeit: 01.01.2020 - 31.12.2024
imported
Kurzfassung
Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Laufzeit: 01.01.2020 - 31.12.2024
Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)